

Comparative Performance of AI vs Radiologists in Pre-Biopsy mpMRI Prostate Cancer Diagnosis: A Systematic Review and Meta-Analysis of Multi-Centre, Multi-Vendor Studies

Aaditya Tiwari, Uzair Khan, Karran Bhagat, Tulika Nahar, Soumya Arun, Aruni Ghose, Abel Tesfai, Alexandra Naranjo, Pinky Kotecha, Nicolas Omorphos, Joecelyn Kirani Tan, Maryam Hasanova, Akash Maniam, Giuseppe Banna, Yüksel Ürün, Swarupa Mitra, Karan Jatwani, Stergios Boussios, Prasanna Sooriakumaran, Benjamin Lamb, Jeremy Teoh, Antony Rix, Amy Rylance, Balraj Dhesi, Atif Khan, Sola Adeleke

Introduction

- PROMIS trial (2017)
- Landmark study demonstrating mpMRI superiority over TRUS for csPC
- Prostate mpMRI is **standard** in diagnosing csPC
- AI-based tools offer support to **enhance mpMRI-based decision-making**

Objectives


- EAU recommendation: upfront implementation of mpMRI in biopsy-naive patients
- Systematic review of AI vs radiologists to diagnose prostate cancer from pre-biopsy prostate MRI in a **multi-centre, multi-vendor setting**

Results

Metric	AI Models	Radiologists
AUC	0.837	0.75
Sensitivity	90.6%	91.2%
Specificity	67.1%	51.3%

Pooled AUC, sensitivity, and specificity

Methods



Study	AI System Used	Sensitivity	Specificity	AUC	Strengths	Weaknesses
Giganti et al.	Prostate Intelligence (Pi v2.4)	95%	67%	0.91	High sensitivity; Generalizable across multi-center, multi-vendor datasets; CE-marked clinical AI	Slightly lower specificity than radiologists; Missed 14% of lesions ; Performance varies across sites
Jaouen et al.	Radiomic-based CAD (Standalone & Second Reader)	84%	83%	0.88	Improved performance when used as second reader; High diagnostic accuracy	Performance affected by lesion zone and reader experience
Castillo et al.	Radiomics model using WORC	88%	63%	0.75	Outperforms radiologists in multi-center setting; Good generalizability	Performance drops significantly on external datasets ; High dependency on scanning protocols and delineation

Model 1 – Prostate intelligence: detected csPC against MDT-supported radiologists
 Model 2 – radiomics-based, zone-specific ROI CAD aligned with PI-RADSv2
 Model 3 – radiomics-based WORC using logistic regression, SVM, random forest, and naive Bayes models

A meta-analysis including 552 pre-biopsy patients

Pooled sensitivity: 0.884 (95% CI: 0.75-0.98)

Pooled specificity: 0.681 (95% CI: 0.51 – 0.80)

AUC 0.837 (95% CI: 0.690 – 0.950)

Pooled analysis of 552 patients pre-biopsy → Model 1 and Model 2 comparable to radiologists.
 Model 3 demonstrated superior performance to radiologists

Conclusions

- MpMRI-directed prostate biopsy pathway increases clinically-significant prostate cancer detection
- Decreased prostate cancer negative biopsy rates
- Implies reduced labour-intensive radiology workforce pressure and time constraints
- AI prostate cancer diagnostic accuracy is comparable to radiologists



References